The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography EvidenceNCT07228234
Evaluating Mammography Communication Approaches
A study testing Harm/benefit language vs. outcomes that can happen and Breast cancer survivability information in people with The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography Evidence, run by University of Colorado, Denver at 1 site in United States.
Trial summary
This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to experimental conditions which vary whether screening outcomes are referred to as "benefits and harms" vs. Read more about this study
- Who is it for?
- Ages 39 to 49 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography Evidence
- What is being tested?
- Harm/benefit language vs. outcomes that can happen and Breast cancer survivability information
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,900 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Nov 2025to 30 Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 39 to 49 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Female, age 39-49
Who cannot join
- No history of breast cancer, no known BRCA1/2 gene mutation
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Colorado Anschutz
Aurora, Colorado, 80045
About this study
This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to experimental conditions which vary whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and vary the presence or absence of information about improvements in breast cancer survivability. In a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.
Read the detailed description
This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to 1 of 5 experimental conditions, in a 2 x 2 + 1 factorial design, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.
- Being tested
- Harm/benefit language vs. outcomes that can happen, Breast cancer survivability information, No intervention
- Keywords
- Communication, Mammography
- Medical subject headings
- Communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Harm/benefit language vs. outcomes that can happenOther
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Breast cancer survivability informationOther
Information about improvements over time in the survivability of breast cancer is provided vs. not
No interventionOther
This is the control condition in which only basic information about mammography screening.
| Study group | Role | What they receive |
|---|---|---|
| Control condition | Experimental | Participants receive basic information about what mammography screening is Receives: Other: No intervention |
| Harm/benefit language, survivability information | Experimental | Outcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is included Receives: Other: Harm/benefit language vs. outcomes that can happen; Other: Breast cancer survivability information |
| Harm/benefit language, no survivability information | Experimental | Outcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is not included Receives: Other: Harm/benefit language vs. outcomes that can happen |
| Outcomes that can happen language, survivability information | Experimental | Outcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is included Receives: Other: Harm/benefit language vs. outcomes that can happen; Other: Breast cancer survivability information |
| Outcomes that can happen language, no survivability information | Experimental | Outcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is not included Receives: Other: Harm/benefit language vs. outcomes that can happen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skepticism toward the screening message
Skepticism toward the screening message is assessed using the RED scale, consisting of 11 questions each measured on a 7-point Likert scale
Measured: Participant experience entails a one-time survey. This outcome is measured in that survey, immediately after participants read information about mammography screening.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study start6 Nov 2025
- Primary completion12 Nov 2025
- Study completion30 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography EvidenceStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- This is a 2 x 2 +1 randomized factorial design. Participants will be randomly assigned to 1 of 5 experimental conditions, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions).
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07228234
- Sponsor's protocol ID
- 25-0635.cc
- Other IDs
- R37CA254926
- Status last verified
- Mar 2026
- First submitted
- 11 Nov 2025
- Last updated
- 1 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Although these data are anonymized, data will be checked for any potentially identifying information. Any such information will be removed from the data prior to data sharing. The full data (sans potential identifiers) will be made publicly available on the Open Science Framework.
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Mammography Communication Approaches
- ClinicalTrials.gov ID
- NCT07228234
- Acronym / sponsor ID
- 25-0635.cc
- Keywords
- Communication, Mammography
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,900 participants (estimated)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 6 Nov 2025 (actual)
- Primary completion
- 12 Nov 2025 (actual)
- Study completion
- 30 Nov 2027 (estimated)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to experimental conditions which vary whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and vary the presence or absence of information about improvements in breast cancer survivability. In a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.
Detailed description
This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to 1 of 5 experimental conditions, in a 2 x 2 + 1 factorial design, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 5
- Model description
- This is a 2 x 2 +1 randomized factorial design. Participants will be randomly assigned to 1 of 5 experimental conditions, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions).
| Arm | Type | Receives |
|---|---|---|
| Control condition | Experimental | Other: No interventionParticipants receive basic information about what mammography screening is |
| Harm/benefit language, survivability information | Experimental | Other: Harm/benefit language vs. outcomes that can happen, Other: Breast cancer survivability informationOutcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is included |
| Harm/benefit language, no survivability information | Experimental | Other: Harm/benefit language vs. outcomes that can happenOutcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is not included |
| Outcomes that can happen language, survivability information | Experimental | Other: Harm/benefit language vs. outcomes that can happen, Other: Breast cancer survivability informationOutcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is included |
| Outcomes that can happen language, no survivability information | Experimental | Other: Harm/benefit language vs. outcomes that can happenOutcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is not included |
Who may qualify
- Ages
- 39 to 49 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Female, age 39-49
Key exclusion criteria (1 listed)
- No history of breast cancer, no known BRCA1/2 gene mutation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Harm/benefit language vs. outcomes that can happenInformation about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen". | Other | Harm/benefit language, no survivability information, Harm/benefit language, survivability information, Outcomes that can happen language, no survivability information, Outcomes that can happen language, survivability information |
| Breast cancer survivability informationInformation about improvements over time in the survivability of breast cancer is provided vs. not | Other | Harm/benefit language, survivability information, Outcomes that can happen language, survivability information |
| No interventionThis is the control condition in which only basic information about mammography screening. | Other | Control condition |
Primary outcome
Skepticism toward the screening message
Time frame: Participant experience entails a one-time survey. This outcome is measured in that survey, immediately after participants read information about mammography screening.
Skepticism toward the screening message is assessed using the RED scale, consisting of 11 questions each measured on a 7-point Likert scale
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
- Individual participant dataSharing planned: Yes. Although these data are anonymized, data will be checked for any potentially identifying information. Any such information will be removed from the data prior to data sharing. The full data (sans potential identifiers) will be made publicly available on the Open Science Framework.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Harm/benefit language vs. outcomes that can happen and Breast cancer survivability information in people with The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography Evidence, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skepticism toward the screening message (time frame: Participant experience entails a one-time survey. This outcome is measured in that survey, immediately after participants read information about mammography screening.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.